Was appointed as a Director in February 2018, and the CEO and the Chief Scientific Officer in February 2021. He was re-designated as an executive Director in February 2021.

 Dr. Li has also held positions at CARsgen Therapeutics. He has been a director and the chief executive officer since October 2014, and the chief scientific officer since December 2017.

Dr. Li has approximately 20 years of work experience in the biopharmaceutical field. Prior to joining our Group, Dr. Li was a project manager at Guilin Pavay Gene Pharmaceutical Co., Ltd. from July 2000 to April 2002. Dr. Li worked at Shanghai Cancer Institute from July 2005 to June 2018 and served as the leader of the biotherapy research team at the State Key Laboratory of Oncogenes and Related Genes of Shanghai Cancer Institute during such period.

Dr. Li has dedicated himself to developing innovative treatment for the patients with cancer. One of his early career achievements is the identification of GE11, a peptide ligand of EGFR which has become a widely used unnatural peptide in antitumor study now. He is also the inventor of new technologies such as Hpd3cell, a new phage display technology; FR806, a new safety switch for T cell therapy; CycloCAR technology to increase the antitumor activities of chimeric antigen receptor (CAR) T cells. He has a leading role in the research on CAR T cell therapy against solid tumors by publishing the first paper of CAR T cell therapy against GPC3, Claudin18.2 and EGFR/EGFRvIII worldwide. Dr. Li was a professor in Shanghai Cancer Institute, Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine and a doctoral supervisor at Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine.

Dr. Li obtained his bachelor’s degree in preventive medicine and master’s degree in pathology and pathophysiology from the Central South University, formerly known as the Hunan Medical University, the PRC, in June 1997 and July 2000 respectively. He obtained his Doctor of Philosophy degree in pathogen biology from Fudan University, the PRC, in June 2005.

Dr. Li was awarded the Leading Talents of Shanghai City in 2018, the Shanghai Youth Science and Technology Award, and the Shanghai May 1st Labor Medal in 2019.

Was appointed as a Director in September 2018 and the COO in February 2021. He was re-designated as an executive Director in February 2021.

Dr. Wang has also held positions at other members of our Group. He has been a director and the chief operating officer of CARsgen Therapeutics since October 2014, the general manager of CARsgen Pharmaceuticals since November 2017 and the general manager of CARsgen Diagnostics since November 2020.

Prior to joining our Group, Dr. Wang worked at Zhejiang Academy of Medical Sciences from July 2009 to January 2011, served as the deputy general manager of Shanghai Ruijin Biotechnology Co., Ltd. from January 2011 to June 2013, and the general manager of YIJIE Biotech (Shanghai) from July 2013 to October 2014.

Dr. Wang obtained his bachelor’s degree in biochemistry from Sichuan University, the PRC, in June 1999. He received his master’s degree and Doctor of Philosophy degree in pathogenic organisms from Fudan University, the PRC, in June 2003 and June 2009, respectively.

Dr. Baffa has rich experiences in pharmaceutical industry and research institutes, taking various leadership positions in multi-national corporations and biotech companies. Prior to joining CARsgen, Dr. Baffa served as Chief Medical Officer and Executive Vice President of Research & Development at Ziopharm Oncology (NASDAQ: ZIOP), which was rebranded to Alaunos in January 2022. (NASDAQ: TCRT). Prior to Ziopharm Oncology, Dr. Baffa was Head of Research & Development and Chief Medical Officer in Medisix Therapeutics, a company focused on developing novel immune cell therapies. Dr. Baffa was the Vice President, Therapeutic Area Head of Oncology, Global Clinical Development of Shire Pharmaceuticals, and following the acquisition of the oncology division by Servier Pharmaceuticals, Dr. Baffa served as the Chief Medical Officier of Servier Pharmaceuticals. Dr. Baffa has also held leadership positions at well-known pharmaceutical companies, such as Pfizer and Sanofi.

Dr. Baffa earned an M.D. from University of Padova, School of Medicine and a Ph.D. in biology and molecular pathology from University of Parma in Italy.

Mr. Daly has approximately 30 years of experience in pharmaceutical industry, including leadership positions in multi-national corporations and biotech companies. Prior to joining our Group, Mr. Daly served as Chief Operating Officer of Beyond Spring, Inc. (NASDAQ: BYSI). From February 2016 to July 2018, Mr. Daly served as Chief Executive Officer, President and Chairman of Neuralstem, Inc. (NASDAQ: PALI). Mr. Daly served in AstraZeneca as the President of the U.S. Diabetes subsidiary (formerly BMS-AZ Diabetes Alliance). Prior to these positions, from 1998 to 2011, Mr. Daly served at Takeda and TAP Pharmaceuticals, a joint venture established between Takeda and Abbott Laboratories, holding several leadership positions, including the Executive Vice President at Takeda Pharmaceutical North America and the Senior Vice President of marketing at TAP Pharmaceuticals. Mr. Daly currently sits on the boards of directors of Catalyst Pharmaceuticals (NASDAQ: CPRX) and Opiant Pharmaceuticals (NASDAQ:OPNT).

Mr. Daly holds an MBA from Kellogg School of Management at Northwestern University and a Bachelor of Science degree from University of Notre Dame.

Dr. Hsu has over 15 years of work experience in business management and strategic planning in the biotechnology industry. Prior to joining our Group, Dr. Hsu served as director of business development at Acadia Pharmaceuticals (NASDAQ: ACAD) and vice president of corporate development and strategy at Lpath, Inc. (merged with Apollo Endosurgery, Inc. in December 2016) between January 2005 and November 2016.

Dr. Hsu obtained his bachelor’s degree in biochemistry and cell biology and his doctorate degree in molecular pathology from the University of California, San Diego in the United States, in June 1993 and September 1999, respectively. He received his master’s degree in business administration from the University of California, Irvine in the United States, in June 2001.

Dr. Jia has served in CARsgen Therapeutics Corporation, our wholly-owned subsidiary incorporated in the United States since joining our Group, including as the Vice President, Business Development responsible for overseeing the corporate operations of the Group in the United States, leading the strategic alliances and managing CMC operations from December 2016 to July 2017, as the Vice President, Strategic Alliances responsible for overseeing the corporate operations in the United States, leading strategic alliances, managing CMC operations from July 2017 to December 2018, and as the Vice President, Strategic Alliances and Operations responsible for overseeing the corporate operations in the United States, leading strategic alliances, managing CMC operations from January 2019 to present.

Dr. Jia obtained his bachelor’s degree in biochemistry from Sichuan University, the PRC, in July 1999 and his doctorate degree in biochemistry and molecular biology from Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, the PRC, in August 2004. He has been a member of The North American Vascular Biology Organization and Sigma Xi since 2006 and 2008, respectively. In 2014, he joined The Nitric Oxide Society as a member. He became a member of American Association for the Advancement of Science in 2016. Dr. Jia joined the American Society of Clinical Oncology as an allied physician and doctoral scientist in 2017. He has been a member of the American Society of Hematology and a full member of the American Society of Quality since 2019.

Dr. Jiang has about 18 years of working experiences in the field of cancer biotherapy. She currently serves as Vice President of Early Discovery of CARsgen, responsible for formulating the strategy of early discovery and the construction of R&D pipeline. Dr. Jiang joined the Company in April 2021 as Senior Director of Immune Cell Research and Development Department, responsible for the research work of Immune Cell Research and Development and Preclinical Pharmacology. Dr. Jiang has contributed significantly to the early research, technology platform development, and innovative products development in CARsgen. Prior to joining the Company, from July 2007 to April 2021, Dr. Jiang worked at Shanghai Cancer Institute, responsible for the research and development of antibody and CAR T cells, as well as the related mechanisms. Dr. Jiang was a professor at Shanghai Cancer Institute and a doctoral supervisor at Shanghai Jiao Tong University School of Medicine.

Dr. Jiang has published more than 20 SCI papers in journals such as Journal of the National Cancer Institute, Clinical Cancer Research, Molecular Therapy, etc. She is the first author to publish the world's first CLDN18.2 CAR T and first EGFR/EGFRvIII CAR T papers and the co-corresponding author to publish the world's first paper on the combination therapy of small molecule and CAR T cells for the treatment of solid tumors.

Dr. Jiang earned her Bachelor’s degree in Clinical Medicine from Jining Medical College in 2001. She obtained Master's degree in Pathogen Biology from Shandong University in 2004 and Ph.D. in Pathogen Biology from Fudan University in 2007.

Dr. Ma was the director of clinical operations at Endocyte, Inc. (NASDAQ: ECYT) from June 2012 to July 2014. He then worked as a temporary employee at Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) from September 2014 to December 2014 and served as the director of clinical development from December 2014 to May 2016. Dr. Ma served as the senior medical director at Immatics US, Inc., a joint venture launched by Immatics Biotechnologies GmbH (NASDAQ: IMTX) and MD Anderson Cancer Center from May 2016 to August 2018.

Dr. Ma obtained his bachelor’s degree in clinical medicine and his master’s degree in cancer pathophysiology from Central South University, formerly known as Hunan Medical University), the PRC, in July 1994 and July 1997, respectively. He received his master’s degree in business administration from University of Georgia, the United States, in May 2005. Dr. Ma has been elected as an Allied Physician/Doctoral Scientist of the American Society of Clinical Oncology since 2011. He has also been a member of the American Society of Hematology since 2016.

Dr. Peltier has extensive global leadership and hands-on experiences in clinical and CMC regulatory affairs across several multinational pharmaceutical and biopharmaceutical companies. Prior to joining CARsgen, Dr. Peltier served as Vice President, Head of US Regulatory Affairs at MorphoSys US Inc (NASDAQ: MOR) since 2020, and as Head of Regulatory Affairs at Servier Pharmaceuticals LLC from 2018. Before joining Servier Pharmaceuticals LLC, Dr. Peltier served at Cephalon since 2007, an international biopharmaceutical company which was acquired later by TEVA Pharmaceuticals Industries Ltd (NYSE: TEVA), holding various positions from Senior Director, Europe Regulatory Affairs, CNS/Pain and CMC, Senior Director, US Regulatory Affairs, to Senior Director, Clinical Search Evaluation and Due Diligence. Previously, Dr. Peltier worked at Pfizer Regulatory Affairs from 1995.

Dr. Peltier earned a Diploma of Pharmacy Doctorate and a Diploma of Graduated Specialized Studies (DESS) in Health Law from University of Paris XI in Paris, France.

Dr. Wang previously worked at Xiangya Hospital of Central South University. She also worked at Hangzhou MSD Pharmaceutical Co. Ltd. – Shanghai Branch from January 2007 to August 2011, where she was responsible for the medical affairs in the medical department. Dr. Wang then served at Beijing Novartis Pharma Co., Ltd. as a senior medical scientific expert from September 2011 to May 2012. Prior to joining our Group, Dr. Wang served as the associate safety risk lead and subsequently the clinical program lead at the China R&D center of Pfizer (China) Research and Development Co., Ltd. from May 2012 to May 2018.

Dr. Wang obtained her bachelor’s degree in clinical medicine from Central South University, formerly known as Hunan Medical University, the PRC, in June 1997. She obtained her master’s degree in clinical medicine and doctorate degree in pediatrics from Central South University and Fudan University, the PRC, in June 2003 and July 2007, respectively.

Prior to joining our Company, Ms. Xie served as the vice president, finance of Connect Biopharma (Shanghai) Co., Ltd., a subsidiary of Connect Biopharma Holdings Limited (NASDAQ: CNTB) from October 2020 to March 2021 during which she was responsible for U.S. listing, finance and tax related matters. Prior to this, Ms. Xie served as the chief financial officer of Sunshine Guojian Pharmaceuticals (Shanghai) Co., Ltd. (SSE Sci-Tech Innovation Board: 688336) from April 2019 to May 2020 and she was the vice president and the chief financial officer (China region) of SciClone Pharmaceuticals (China) Co., Ltd., a wholly-owned subsidiary of SciClone Pharmaceuticals Holdings Limited (HKEX: 6600) from August 2012 to September 2018. From November 2007 to July 2012, Ms. Xie served as the vice president, finance of Shanghai ChemPartner Co., Ltd. Ms. Xie was a senior manager in PricewaterhouseCoopers Consultants, Shenzhen Co., Ltd. Shanghai Branch from August 2005 to November 2007 and was responsible for corporate mergers and acquisitions and financial due diligence related work.

Ms. Xie obtained her bachelor’s degree in business administration in Boston University in May 1994. She has also earned a master of business administration degree (MBA) in INSEAD in July 2003.

MS.Jiang Caihua has more than 30 years’ experience in quality management, successfully leading multiple teams through global regulatory inspections for various drug products. Prior to joining CARsgen, she served as Sr. VP of Global Quality Operations in Henlius Biotech, VP of Global Quality and Compliance in TWi Pharmaceuticals, Quality Director in Boehringer Ingelheim and Stryker, and quality management positions in Novartis, Perrigo and BMS.

MS.Jiang Caihua earned her Master of Microbiology degree from University of Wisconsin-Madison and Bachelor of Applied Chemistry degree from China Agricultural University.

Dr.Zhou Guanjun had served as several critical public official roles in Jiangsu Province and Shanghai for over 15 years. He is familiar with government departments management and decision-making systems and procedures.

Prior to joining CARsgen,  Dr. Zhou was Vice President of Government Relations of Biren Technology, successively served as Director of the Office and Director of Price Monitoring and Supervision Department, Shanghai Municipal Development and Reform Commission.

Dr. Zhou earned his Ph.D and Master degree of Economics at Capital University of Economics and Business, in 2005 and 2002 respectively. He earned his Bachelor degree of Electrical Engineering in Harbin Engineering University in 1996.